Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 8/20 | 0.36 |
| ▸ | SLC6A5 | Q9Y345 | 4/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 2/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL375116 | 0.91 | KDM4E (0.40) | SLC6A9SLC6A5KCNH2CYP3A4KDM4E | |
| SCHEMBL2686649 | 0.90 | AGER (0.41) | SLC6A9SLC6A5KCNH2CYP3A4KDM4E | |
| SCHEMBL375173 | 0.87 | SLC6A9 (0.42) | SLC6A9SLC6A5KCNH2CYP3A4ALDH1A1 | |
| SCHEMBL374833 | 0.85 | SLC6A9 (0.39) | SLC6A9SLC6A5KCNH2CYP3A4NSD2 | |
| SCHEMBL375110 | 0.84 | SLC6A9 (0.53) | SLC6A9SLC6A5KCNH2CYP3A4ALDH1A1 | |
| SCHEMBL375594 | 0.84 | KCNH2 (0.39) | SLC6A9SLC6A5KCNH2CYP3A4CYP2D6 | |
| SCHEMBL375183 | 0.82 | SLC6A9 (0.40) | SLC6A9SLC6A5KCNH2CYP3A4CYP2D6 | |
| SCHEMBL375145 | 0.82 | SLC6A4 (0.49) | KCNH2CYP3A4CYP2D6CYP1A2CYP2C9 | |
| SCHEMBL375147 | 0.81 | TACR1 (0.41) | SLC6A9SLC6A5KCNH2TACR1 | |
| SCHEMBL375006 | 0.81 | PDE4D (0.39) | SLC6A9SLC6A5KCNH2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729271-B2 | Glycine transporter inhibiting substances | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2014-05-20 | — | — | US | disclosed |
| US-8623898-B2 | Glycine transporter inhibiting substances | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-01-07 | — | — | US | disclosed |
| EP-2617715-A1 | GLYCINE TRANSPORTER INHIBITOR | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2013-07-24 | — | — | EP | disclosed |
| US-20130184460-A1 | GLYCINE TRANSPORTER INHIBITING SUBSTANCES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-07-18 | — | — | US | disclosed |
| EP-2409976-A1 | GLYCINE TRANSPORTER INHIBITOR | Taisho Pharmaceutical Co., Ltd. (JP) | 2012-01-25 | — | — | EP | disclosed |
| US-20120010414-A1 | GLYCINE TRANSPORTER INHIBITING SUBSTANCES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184460-A1 | GLYCINE TRANSPORTER INHIBITING SUBSTANCES | SLC1A2, SLC18A2, SLC6A1 | SLC6A9 7/4885SLC6A5 4/4885KCNH2 1435/4885 |
| US-20120010414-A1 | GLYCINE TRANSPORTER INHIBITING SUBSTANCES | SLC18A2, SLC1A2, SLC6A1 | SLC6A9 8/4885SLC6A5 4/4885KCNH2 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.